Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: A case report

Alberto Bongiovanni, Nada Riva, Marianna Ricci, Laura Mercatali, Chiara Liverani, Federico La Manna, Alessandro De Vita, Davide Cavaliere, Federica Pieri, Devil Oboldi, Giorgio Maria Verdecchia, Dino Amadori, Toni Ibrahim

Research output: Contribution to journalArticle

Abstract

Background: Leiomyosarcoma (LMS) is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. The prognosis for this tumor is poor, with survival rates among the lowest of all soft tissue sarcomas. Surgery is the best approach for localized disease. The principal role of chemotherapy is prevalently in the treatment of metastatic disease. Trabectedin, a promising new DNA-damaging agent with a mechanism of action that differs from that of traditional alkylating agents, has been approved in Europe for the treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, Case presentation: We report the case of a 53-year-old woman with metastatic well differentiated uterine leiomyosarcoma refractory to multiple treatments who underwent 22 cycles of trabectedin over 30 months, obtaining a partial response according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria, with good tolerability, and maintaining the response for 10 months after trebectedin withdrawal. Conclusion: This very prolonged response, which persisted after drug discontinuation, suggests that trabectedin exerts an oncostatic effect rather than the cytotoxic one produced by other chemotherapeutic agents. Our experience also raises the question of the best way to evaluate trabectedin efficacy.

Original languageEnglish
Article number998
JournalBMC Cancer
Volume15
Issue number1
DOIs
Publication statusPublished - Dec 22 2015

Fingerprint

trabectedin
Leiomyosarcoma
Sarcoma
Ifosfamide
Alkylating Agents
Anthracyclines
Smooth Muscle Myocytes
Therapeutics
Survival Rate
Drug Therapy
DNA

Keywords

  • Soft tissue sarcoma
  • Trabectedin
  • Uterine leiomyosarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma : A case report. / Bongiovanni, Alberto; Riva, Nada; Ricci, Marianna; Mercatali, Laura; Liverani, Chiara; La Manna, Federico; De Vita, Alessandro; Cavaliere, Davide; Pieri, Federica; Oboldi, Devil; Verdecchia, Giorgio Maria; Amadori, Dino; Ibrahim, Toni.

In: BMC Cancer, Vol. 15, No. 1, 998, 22.12.2015.

Research output: Contribution to journalArticle

Bongiovanni, Alberto ; Riva, Nada ; Ricci, Marianna ; Mercatali, Laura ; Liverani, Chiara ; La Manna, Federico ; De Vita, Alessandro ; Cavaliere, Davide ; Pieri, Federica ; Oboldi, Devil ; Verdecchia, Giorgio Maria ; Amadori, Dino ; Ibrahim, Toni. / Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma : A case report. In: BMC Cancer. 2015 ; Vol. 15, No. 1.
@article{54dd3ef590c947fb81fb5f22b11730f8,
title = "Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: A case report",
abstract = "Background: Leiomyosarcoma (LMS) is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. The prognosis for this tumor is poor, with survival rates among the lowest of all soft tissue sarcomas. Surgery is the best approach for localized disease. The principal role of chemotherapy is prevalently in the treatment of metastatic disease. Trabectedin, a promising new DNA-damaging agent with a mechanism of action that differs from that of traditional alkylating agents, has been approved in Europe for the treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, Case presentation: We report the case of a 53-year-old woman with metastatic well differentiated uterine leiomyosarcoma refractory to multiple treatments who underwent 22 cycles of trabectedin over 30 months, obtaining a partial response according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria, with good tolerability, and maintaining the response for 10 months after trebectedin withdrawal. Conclusion: This very prolonged response, which persisted after drug discontinuation, suggests that trabectedin exerts an oncostatic effect rather than the cytotoxic one produced by other chemotherapeutic agents. Our experience also raises the question of the best way to evaluate trabectedin efficacy.",
keywords = "Soft tissue sarcoma, Trabectedin, Uterine leiomyosarcoma",
author = "Alberto Bongiovanni and Nada Riva and Marianna Ricci and Laura Mercatali and Chiara Liverani and {La Manna}, Federico and {De Vita}, Alessandro and Davide Cavaliere and Federica Pieri and Devil Oboldi and Verdecchia, {Giorgio Maria} and Dino Amadori and Toni Ibrahim",
year = "2015",
month = "12",
day = "22",
doi = "10.1186/s12885-015-2038-7",
language = "English",
volume = "15",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma

T2 - A case report

AU - Bongiovanni, Alberto

AU - Riva, Nada

AU - Ricci, Marianna

AU - Mercatali, Laura

AU - Liverani, Chiara

AU - La Manna, Federico

AU - De Vita, Alessandro

AU - Cavaliere, Davide

AU - Pieri, Federica

AU - Oboldi, Devil

AU - Verdecchia, Giorgio Maria

AU - Amadori, Dino

AU - Ibrahim, Toni

PY - 2015/12/22

Y1 - 2015/12/22

N2 - Background: Leiomyosarcoma (LMS) is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. The prognosis for this tumor is poor, with survival rates among the lowest of all soft tissue sarcomas. Surgery is the best approach for localized disease. The principal role of chemotherapy is prevalently in the treatment of metastatic disease. Trabectedin, a promising new DNA-damaging agent with a mechanism of action that differs from that of traditional alkylating agents, has been approved in Europe for the treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, Case presentation: We report the case of a 53-year-old woman with metastatic well differentiated uterine leiomyosarcoma refractory to multiple treatments who underwent 22 cycles of trabectedin over 30 months, obtaining a partial response according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria, with good tolerability, and maintaining the response for 10 months after trebectedin withdrawal. Conclusion: This very prolonged response, which persisted after drug discontinuation, suggests that trabectedin exerts an oncostatic effect rather than the cytotoxic one produced by other chemotherapeutic agents. Our experience also raises the question of the best way to evaluate trabectedin efficacy.

AB - Background: Leiomyosarcoma (LMS) is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. The prognosis for this tumor is poor, with survival rates among the lowest of all soft tissue sarcomas. Surgery is the best approach for localized disease. The principal role of chemotherapy is prevalently in the treatment of metastatic disease. Trabectedin, a promising new DNA-damaging agent with a mechanism of action that differs from that of traditional alkylating agents, has been approved in Europe for the treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, Case presentation: We report the case of a 53-year-old woman with metastatic well differentiated uterine leiomyosarcoma refractory to multiple treatments who underwent 22 cycles of trabectedin over 30 months, obtaining a partial response according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria, with good tolerability, and maintaining the response for 10 months after trebectedin withdrawal. Conclusion: This very prolonged response, which persisted after drug discontinuation, suggests that trabectedin exerts an oncostatic effect rather than the cytotoxic one produced by other chemotherapeutic agents. Our experience also raises the question of the best way to evaluate trabectedin efficacy.

KW - Soft tissue sarcoma

KW - Trabectedin

KW - Uterine leiomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84951819569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951819569&partnerID=8YFLogxK

U2 - 10.1186/s12885-015-2038-7

DO - 10.1186/s12885-015-2038-7

M3 - Article

AN - SCOPUS:84951819569

VL - 15

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 998

ER -